Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort.
Chikako OhwadaEmiko SakaidaYusuke TakedaNoriko DokiAiko IgarashiMakoto OnizukaMasako ToyosakiMasatsugu TanakaTakayoshi TachibanaKeisuke KataokaJun KatoShin FujisawaSeiko KatoHideki NakasoneKen NaganumaTakayuki SaitohKatsuhiro ShonoMaki HagiharaTakeshi SaitoKensuke UsukiTakehiko MoriChiaki NakasekoShinichiro OkamotoYoshinobu KandaPublished in: International journal of hematology (2024)
A prospective multicenter observational study of organ response was conducted in patients with chronic GVHD diagnosed by the NIH criteria. When response was assessed at 12 months (12 M) in 118 patients, 74.6% were classified as responders and 25.4% as non-responders. The skin and oral cavity were the most frequent organs used as the basis for determining overall response. The lungs, liver, and eyes were also used in 20% of patients. Non-response decisions at 12 M were most frequent in the lungs. A significantly higher percentage of responders than non-responders completed systemic treatment (24.3% vs. 3.3%, P = 0.02). Global scoring showed significant changes, with improvement in responders and worsening in non-responders throughout the observation period. Two-year transplant-related mortality, using the 12 M assessment as the landmark, was significantly worse in non-responders (28.5% vs. 2,7%, P = 0.0001), while the 2-year recurrence rate was equivalent (5.4% vs. 4.8%, P = 0.78). Consequently, the 2-year overall survival rate from the 12 M assessment was significantly better in responders than non-responders (95% vs. 65.3%, P = 0.0001). Our data suggests that patients who do not achieve a response within the first year should be candidates for clinical studies on chronic GVHD.
Keyphrases
- end stage renal disease
- newly diagnosed
- type diabetes
- prognostic factors
- peritoneal dialysis
- cross sectional
- clinical trial
- machine learning
- allogeneic hematopoietic stem cell transplantation
- patient reported outcomes
- acute myeloid leukemia
- coronary artery disease
- free survival
- big data
- smoking cessation
- patient reported
- clinical evaluation